Published in Antimicrob Agents Chemother on August 01, 1999
Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob Agents Chemother (2007) 1.10
Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice. Antimicrob Agents Chemother (2000) 1.03
In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrob Agents Chemother (2006) 0.91
Absolute bioavailability and disposition of (-) and (+) 2'-deoxy- 3'-oxa-4'-thiocytidine (dOTC) following single intravenous and oral doses of racemic dOTC in humans. Antimicrob Agents Chemother (2000) 0.84
In vitro interactions between apricitabine and other deoxycytidine analogues. Antimicrob Agents Chemother (2007) 0.84
Critical design features of phenyl carboxylate-containing polymer microbicides. Antimicrob Agents Chemother (2006) 0.82
Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob Agents Chemother (2007) 0.80
Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations. Antimicrob Agents Chemother (2009) 0.78
Safety, tolerability, and pharmacokinetics of single oral doses of BCH-10652 in healthy adult males. Antimicrob Agents Chemother (2000) 0.75
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother (1993) 5.08
Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother (1997) 2.64
1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother (1997) 2.31
Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother (1997) 2.15
Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother (1994) 2.10
Biochemical pharmacology of (+)- and (-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents. J Biol Chem (1992) 1.91
Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation. Biochemistry (1992) 1.69
Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother (1997) 1.66
Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs. Proc Natl Acad Sci U S A (1995) 1.56
Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells. Mol Pharmacol (1989) 1.54
Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem Pharmacol (1997) 1.37
Viral resistance and the selection of antiretroviral combinations. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.21
T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1995) 1.11
Cellular pharmacology of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) in human peripheral blood mononuclear cells. Biochem Pharmacol (1990) 1.01
Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro. J Med Chem (1995) 1.01
Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs (1996) 0.97
Inhibition of human cytomegalovirus in culture by alkenyl guanine analogs of the thiazolo[4,5-d]pyrimidine ring system. Antimicrob Agents Chemother (1994) 0.94
2',3'-Dideoxycytidine toxicity in cultured human CEM T lymphoblasts: effects of combination with 3'-azido-3'-deoxythymidine and thymidine. Mol Pharmacol (1990) 0.86
Recent advances in antiretroviral therapy and HIV infection monitoring. Intervirology (1997) 0.85
Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T). Antiviral Res (1995) 0.84
Inhibition of episomal hepatitis B virus DNA in vitro by 2,4-diamino-7- (2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-pyrrolo[2,3-d]pyrimidine. Antimicrob Agents Chemother (1995) 0.80
Determination of brain 5-hydroxytryptamine turnover in freely moving rats using repeated sampling of cerebrovascular fluid. J Neurochem (1983) 0.79
ddC (zalcitabine). Adv Exp Med Biol (1996) 0.78
Hindered diffusion of inert tracer particles in the cytoplasm of mouse 3T3 cells. Proc Natl Acad Sci U S A (1987) 5.19
Probing the structure of cytoplasm. J Cell Biol (1986) 5.10
Traction forces of cytokinesis measured with optically modified elastic substrata. Nature (1997) 4.59
A method for incorporating macromolecules into adherent cells. J Cell Biol (1984) 3.77
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 3.57
The contractile basis of amoeboid movement. I. The chemical control of motility in isolated cytoplasm. J Cell Biol (1973) 3.49
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. J Virol (1992) 3.46
Cytoplasmic structure and contractility in amoeboid cells. Int Rev Cytol (1979) 3.33
The actin-based nanomachine at the leading edge of migrating cells. Biophys J (1999) 3.19
Molecular cytochemistry: incorporation of fluorescently labeled actin into living cells. Proc Natl Acad Sci U S A (1978) 3.18
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 3.00
Role of Pr160gag-pol in mediating the selective incorporation of tRNA(Lys) into human immunodeficiency virus type 1 particles. J Virol (1994) 2.94
The contractile basis of amoeboid movement. V. The control of gelation, solation, and contraction in extracts from Dictyostelium discoideum. J Cell Biol (1977) 2.94
Mobility of cytoplasmic and membrane-associated actin in living cells. Proc Natl Acad Sci U S A (1982) 2.89
Enhancement of axial resolution in fluorescence microscopy by standing-wave excitation. Nature (1993) 2.86
In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine. J Virol (1992) 2.85
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1994) 2.81
Cytoplasmic structure and contractility: the solation--contraction coupling hypothesis. Philos Trans R Soc Lond B Biol Sci (1982) 2.40
Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother (1991) 2.40
Effects of alterations of primer-binding site sequences on human immunodeficiency virus type 1 replication. J Virol (1994) 2.37
Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J Biol Chem (1994) 2.28
Fluorescence ratio imaging microscopy: temporal and spatial measurements of cytoplasmic pH. J Cell Biol (1987) 2.28
Fluorescently labelled molecules as probes of the structure and function of living cells. Nature (1980) 2.27
The contractile basis of ameboid movement. VI. The solation-contraction coupling hypothesis. J Cell Biol (1979) 2.26
Spectrin plus band 4.1 cross-link actin. Regulation by micromolar calcium. J Cell Biol (1980) 2.20
The dynamic distribution of fluorescent analogues of actin and myosin in protrusions at the leading edge of migrating Swiss 3T3 fibroblasts. J Cell Biol (1988) 2.14
Contractile basis of ameboid movement. VII. Aequorin luminescence during ameboid movement, endocytosis, and capping. J Cell Biol (1980) 2.01
The contractile basis of ameboid movement. II. Structure and contractility of motile extracts and plasmalemma-ectoplasm ghosts. J Cell Biol (1976) 2.00
The submicroscopic properties of cytoplasm as a determinant of cellular function. Annu Rev Biophys Biophys Chem (1988) 1.99
Centripetal transport of cytoplasm, actin, and the cell surface in lamellipodia of fibroblasts. Cell Motil Cytoskeleton (1988) 1.96
Distribution of actin in spreading macrophages: a comparative study on living and fixed cells. J Cell Biol (1983) 1.95
Preparation and characterization of a new molecular cytochemical probe: 5-iodoacetamidofluorescein-labeled actin. J Histochem Cytochem (1980) 1.94
Identification of a novel glucocorticoid response element within the genome of the human immunodeficiency virus type 1. Virology (1993) 1.94
Fluorescence photobleaching recovery in solutions of labeled actin. Biophys J (1981) 1.94
Modulation of contraction by gelation/solation in a reconstituted motile model. J Cell Biol (1991) 1.93
Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 1.86
Microspectrofluorometry by digital image processing: measurement of cytoplasmic pH. J Cell Biol (1984) 1.84
The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol (2000) 1.84
High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J Virol (1990) 1.83
Distribution of fluorescently labeled actin in living sea urchin eggs during early development. J Cell Biol (1979) 1.82
Contractile basis of ameboid movement. VII. The distribution of fluorescently labeled actin in living amebas. J Cell Biol (1980) 1.81
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS (1998) 1.81
Local and spatially coordinated movements in Dictyostelium discoideum amoebae during chemotaxis. Cell (1982) 1.75
Relative distribution of actin, myosin I, and myosin II during the wound healing response of fibroblasts. J Cell Biol (1993) 1.74
Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J Infect Dis (1990) 1.73
Keratocytes generate traction forces in two phases. Mol Biol Cell (1999) 1.72
Intracellular pH in single motile cells. J Cell Biol (1980) 1.70
Persistence of cytomegalovirus in mononuclear cells in peripheral blood from blood donors. BMJ (1989) 1.70
Mutations in the kissing-loop hairpin of human immunodeficiency virus type 1 reduce viral infectivity as well as genomic RNA packaging and dimerization. J Virol (1997) 1.68
AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells. Virology (1990) 1.64
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev (1995) 1.63
Myosin II transport, organization, and phosphorylation: evidence for cortical flow/solation-contraction coupling during cytokinesis and cell locomotion. Mol Biol Cell (1996) 1.63
Fluorescent analog cytochemistry of contractile proteins. Methods Cell Biol (1982) 1.63
Rich and cold: diversity, distribution and drivers of fungal communities in patterned-ground ecosystems of the North American Arctic. Mol Ecol (2014) 1.62
Formation, transport, contraction, and disassembly of stress fibers in fibroblasts. Cell Motil Cytoskeleton (1990) 1.61
Detection of actin assembly by fluorescence energy transfer. J Cell Biol (1981) 1.58
Patterns of elevated free calcium and calmodulin activation in living cells. Nature (1992) 1.58
A membrane cytoskeleton from Dictyostelium discoideum. I. Identification and partial characterization of an actin-binding activity. J Cell Biol (1981) 1.58
Probing the dynamic equilibrium of actin polymerization by fluorescence energy transfer. Cell (1981) 1.58
The role of solation-contraction coupling in regulating stress fiber dynamics in nonmuscle cells. J Cell Biol (1991) 1.58
Effects of mutations in Pr160gag-pol upon tRNA(Lys3) and Pr160gag-plo incorporation into HIV-1. J Mol Biol (1997) 1.58
Comparative study of three methods of identification of Enterobacteriaceae. J Clin Microbiol (1977) 1.57
Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs. Proc Natl Acad Sci U S A (1995) 1.56
HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. Arch Biochem Biophys (1999) 1.55
Subcellular compartmentalization by local differentiation of cytoplasmic structure. Cell Motil Cytoskeleton (1988) 1.53
Acute-phase proteins in patients with head and neck cancer treated with interleukin 2/interferon alfa. Arch Otolaryngol Head Neck Surg (1992) 1.52
Gradients in the concentration and assembly of myosin II in living fibroblasts during locomotion and fiber transport. Mol Biol Cell (1993) 1.52
Inhibition of gp160 and CD4 maturation in U937 cells after both defective and productive infections by human immunodeficiency virus type 1. J Virol (1991) 1.50
The role of Pr55(gag) in the annealing of tRNA3Lys to human immunodeficiency virus type 1 genomic RNA. J Virol (1999) 1.49
Incorporation of excess wild-type and mutant tRNA(3Lys) into human immunodeficiency virus type 1. J Virol (1994) 1.49
Acidification of phagosomes is initiated before lysosomal enzyme activity is detected. J Cell Biol (1983) 1.48
Human immunodeficiency virus type 1 reverse transcriptase and early events in reverse transcription. Adv Virus Res (1996) 1.48
The role of nucleocapsid and U5 stem/A-rich loop sequences in tRNA(3Lys) genomic placement and initiation of reverse transcription in human immunodeficiency virus type 1. J Virol (1998) 1.47
Structural organization of interphase 3T3 fibroblasts studied by total internal reflection fluorescence microscopy. J Cell Biol (1985) 1.47
EFFECTS OF OXYGEN ON RESPIRATION, FERMENTATION AND GROWTH IN WHEAT AND RICE. Science (1942) 1.46
fMRI retinotopic mapping--step by step. Neuroimage (2002) 1.45
Fc-receptor-mediated phagocytosis occurs in macrophages without an increase in average [Ca++]i. J Cell Biol (1986) 1.44
Promotion of growth and differentiation of rat ductular oval cells in primary culture. Cancer Res (1988) 1.44
pH changes in pinosomes and phagosomes in the ameba, Chaos carolinensis. J Cell Biol (1982) 1.43
Effects of modifying the tRNA(3Lys) anticodon on the initiation of human immunodeficiency virus type 1 reverse transcription. J Virol (1996) 1.42
A transient rise in cytosolic calcium follows stimulation of quiescent cells with growth factors and is inhibitable with phorbol myristate acetate. J Cell Biol (1985) 1.41
Probing the mechanism of incorporation of fluorescently labeled actin into stress fibers. J Cell Biol (1986) 1.41
Multimode light microscopy and the dynamics of molecules, cells, and tissues. Annu Rev Physiol (1993) 1.39
Initiation of (-) strand DNA synthesis from tRNA(3Lys) on lentiviral RNAs: implications of specific HIV-1 RNA-tRNA(3Lys) interactions inhibiting primer utilization by retroviral reverse transcriptases. Proc Natl Acad Sci U S A (1996) 1.39
Behavior of a fluorescent analogue of calmodulin in living 3T3 cells. J Cell Biol (1985) 1.39
Topographical and physicochemical modification of material surface to enable patterning of living cells. Crit Rev Biotechnol (2001) 1.38
The contractile basis of amoeboid movement. IV. The viscoelasticity and contractility of amoeba cytoplasm in vivo. Exp Cell Res (1977) 1.37
The importance of the A-rich loop in human immunodeficiency virus type 1 reverse transcription and infectivity. J Virol (1997) 1.37
Fluorescence ratio imaging microscopy. Methods Cell Biol (1989) 1.37
K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother (1995) 1.36
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses (1997) 1.36
Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clin Infect Dis (2012) 1.36
The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev (1995) 1.34